TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Brief Summary: To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
D: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Brief Summary: To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients


Options:
A: Arm Label: Treatment (temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: temsirolimus | Intervention Type: DRUG; Name: temsirolimus; Assigned to Arm(s): Treatment (temsirolimus)
B: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: CCI-779 (temsirolimus) | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: CCI-779 (temsirolimus); Assigned to Arm(s): A, B
D: Arm Label: Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD0530, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: AZD0530; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2, Active Comparator | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2, Active Comparator

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.
Brief Summary: To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: KU-0059436; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor) | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): KU-0059436
C: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
D: Intervention Type: DRUG; Name: PARP Inhibitors; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: corifollitropin alfa | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin beta injection | Intervention Type: DRUG; Name: corifollitropin alfa; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Follitropin beta injection; Assigned to Arm(s): 4
B: Arm Label: Oral dydrogesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral dydrogesterone | Arm Label: Crinone 8% vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crinone 8% gel | Intervention Type: DRUG; Name: Oral dydrogesterone; Assigned to Arm(s): Oral dydrogesterone | Intervention Type: DRUG; Name: Crinone 8% gel; Assigned to Arm(s): Crinone 8% vaginal gel
C: Arm Label: Progesterone 5 Weeks; Type: ACTIVE_COMPARATOR; Interventions: Other: Cease progsterone at 5 | Arm Label: Control Group : P4 8 weeks; Type: OTHER; Interventions: Other: control group: progesterone 8 | Intervention Type: OTHER; Name: Cease progsterone at 5; Assigned to Arm(s): Progesterone 5 Weeks | Intervention Type: OTHER; Name: control group: progesterone 8; Assigned to Arm(s): Control Group : P4 8 weeks
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: triptorelin acetate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Na Cl %0.9 | Intervention Type: DRUG; Name: triptorelin acetate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Na Cl %0.9; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours
Brief Summary: The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.


Options:
A: Arm Label: cisplatin and cetuximab; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, cisplatin | Arm Label: cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin | Intervention Type: DRUG; Name: cetuximab, cisplatin; Assigned to Arm(s): cisplatin and cetuximab | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): cisplatin
B: Arm Label: Gemcitabine,cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine,cisplatin | Arm Label: Gemcitabine, Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Paclitaxel | Intervention Type: DRUG; Name: Gemcitabine,cisplatin; Assigned to Arm(s): Gemcitabine,cisplatin | Intervention Type: DRUG; Name: Gemcitabine, Paclitaxel; Assigned to Arm(s): Gemcitabine, Paclitaxel
C: Intervention Type: DRUG; Name: AZD 2281; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Carboplatin | Arm Label: 2.; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Paclitaxel | Arm Label: 3.; Type: EXPERIMENTAL; Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor), Drug: Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 2. | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2. | Intervention Type: DRUG; Name: KU-0059436 (AZD2281)(PARP inhibitor); Assigned to Arm(s): 3. | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): 3.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
Brief Summary: This is a research study designed to examine the effectiveness of an obesity medication (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese monolingual (Spanish-speaking only) men and women.


Options:
A: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Xenical + behavioral intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral intervention + placebo | Intervention Type: DRUG; Name: Xenical + behavioral intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral intervention + placebo; Assigned to Arm(s): 2
C: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Olanzapine (open-label treatment period); Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine (open-label treatment period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters
Brief Summary: This study will test the effectiveness of two different kinds of omega-3 fatty acid dietary supplements in treating the symptoms of major depression.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: EPA omega-3 fatty acid | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA omega-3 fatty acid | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparator | Intervention Type: DIETARY_SUPPLEMENT; Name: EPA omega-3 fatty acid; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA omega-3 fatty acid; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparator; Assigned to Arm(s): C
B: Arm Label: EPA 3.5 g/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: DHA 1.75 g/day; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): DHA 1.75 g/day, EPA 3.5 g/day, Placebo capsules
C: Intervention Type: DRUG; Name: Ethyl-eicosapentanoic acid (ethyl-EPA); Assigned to Arm(s): N/A
D: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-Arm Open-Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous and/or Subcutaneous C.E.R.A for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia
Brief Summary: This single arm study will assess the efficacy and safety of Mircera when administered once monthly, subcutaneously or intravenously, for the maintenance of hemoglobin levels in dialysis patients with chronic renal anemia. Patients currently receiving maintenance treatment with epoetin alfa will receive monthly injections of Mircera with a starting dose (120, 200 or 360 micrograms) derived from the dose of epoetin alfa they were receiving in the week preceding study start. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: C.E.R.A; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): C.E.R.A | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Epoetin Alfa
B: Arm Label: Methoxy Polyethylene Glycol-epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Methoxy Polyethylene Glycol-epoetin Beta | Arm Label: Epoetin Beta or Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Beta, Drug: Darbepoetin Alfa | Intervention Type: DRUG; Name: Methoxy Polyethylene Glycol-epoetin Beta; Assigned to Arm(s): Methoxy Polyethylene Glycol-epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa
C: Arm Label: C.E.R.A; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): C.E.R.A
D: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Administration of a Monophasic Oral Contraceptive in the Treatment of Primary Dysmenorrhea
Brief Summary: The primary hypothesis is that continuous administration of an OCP (CCOCP regimen) will result in more pain relief than a traditional 21/7 administration in primary dysmenorrhea (PD) patients.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Qlarista Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol valerate/dienogest | Arm Label: Yasmin Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ethinylestradiol and drospirenone | Intervention Type: DRUG; Name: estradiol valerate/dienogest; Assigned to Arm(s): Qlarista Group | Intervention Type: DRUG; Name: ethinylestradiol and drospirenone; Assigned to Arm(s): Yasmin Group
B: Arm Label: study group (CCOCP); Type: EXPERIMENTAL; Interventions: Drug: CCOCP | Arm Label: control group (traditional OCP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Traditional OCP | Intervention Type: DRUG; Name: CCOCP; Assigned to Arm(s): study group (CCOCP) | Intervention Type: DRUG; Name: Traditional OCP; Assigned to Arm(s): control group (traditional OCP)
C: Arm Label: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Drug: Placebo Match to SH T00658ID | Arm Label: Ethinyl estradiol, Levonorgestrel (Miranova); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ethinyl estradiol, Levonorgestrel (Miranova), Drug: Placebo Match to SH D593B | Intervention Type: DRUG; Name: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Ethinyl estradiol, Levonorgestrel (Miranova); Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova) | Intervention Type: DRUG; Name: Placebo Match to SH T00658ID; Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo Match to SH D593B; Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova)
D: Arm Label: NPC-01; Type: EXPERIMENTAL; Interventions: Drug: NPC-01 | Arm Label: IKH-01; Type: ACTIVE_COMPARATOR; Interventions: Drug: IKH-01 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NPC-01; Assigned to Arm(s): NPC-01 | Intervention Type: DRUG; Name: IKH-01; Assigned to Arm(s): IKH-01 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension
Brief Summary: Physical training improves quality of life (QOL) in non-hepatic diseases. It is possible that the same effect happens in patients with cirrhosis and portal hypertension. Hepatic encephalopathy may also benefit from physical activity by increasing ammonia metabolism. The intention of this study is to assess if patients can improve their QOL and hepatic encephalopathy during a physical training program, and to address its safety.


Options:
A: Arm Label: Home based aerobic exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Home based Aerobic exercise training | Arm Label: Usual Care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home based Aerobic exercise training; Assigned to Arm(s): Home based aerobic exercise
B: Arm Label: Exercise + Leucine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Arm Label: Leucine without exercise; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Leucine supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Leucine supplements; Assigned to Arm(s): Exercise + Leucine, Leucine without exercise
C: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension
Brief Summary: Physical training improves quality of life (QOL) in non-hepatic diseases. It is possible that the same effect happens in patients with cirrhosis and portal hypertension. Hepatic encephalopathy may also benefit from physical activity by increasing ammonia metabolism. The intention of this study is to assess if patients can improve their QOL and hepatic encephalopathy during a physical training program, and to address its safety.


Options:
A: Arm Label: Transdermal Magnesium; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Magnesium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Transdermal Magnesium; Assigned to Arm(s): Transdermal Magnesium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Physical training - No encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - No encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Arm Label: Physical training - Early encephalopathy; Type: EXPERIMENTAL; Interventions: Other: Physical training, Other: Diet intervention | Arm Label: Control - Early encephalopathy; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet intervention | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training - Early encephalopathy, Physical training - No encephalopathy | Intervention Type: OTHER; Name: Diet intervention; Assigned to Arm(s): Control - Early encephalopathy, Control - No encephalopathy, Physical training - Early encephalopathy, Physical training - No encephalopathy
C: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Other: Fitness exercise program | Intervention Type: OTHER; Name: Fitness exercise program; Assigned to Arm(s): exercise
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: complex lymphedema therapy | Arm Label: B; Type: OTHER; Interventions: Other: complex lymphedema therapy | Intervention Type: OTHER; Name: complex lymphedema therapy; Assigned to Arm(s): A, B

Answer: B